Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 29

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Aug 7, 2014; 20(29): 9862-9871
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9862

Table 2 RAF, MEK and PI3K/mTOR inhibitors presently in the status of clinical trial in colorectal cancer

Drug	Target	Manufacturer	Phase	Indication
Sorafenib	BRAF	Bayer	II	Colon cancer (combination with cetuximab)
PLX4032	BRAFV600E	Plexxikon	I	Melanoma, colon cancer
XL281	BRAF	Exelixis	I	Solid tumors
GSK1120212	MEK	GlaxoSmithKline	I	Solid tumors, Lymphoma
AZD6244	MEK	AstraZeneca	II	Colon cancer (combination with capecitabine)
AS703026	MEK	EMD Serono	I	Solid tumors
GDC-0973	MEK	Genentech	I	Solid tumors
RO5126766	MEK	Hoffman-La Roche	I	Solid tumors
TAK-733	MEK	Millenium	I	Solid tumors
RDEA119	MEK	Ardea Biosciences	I	Solid tumors
BGT226	PI3K	Novartis	I/II	Solid tumors, Her2 positive Breast Cancer
XL147	PI3K	Exelixis	I	Solid tumors, Lymphoma
XL765	PI3K	Exelixis	I	Solid tumors
BEZ235	PI3K	Novartis	I	Solid tumors
GDC-0941	PI3K	Genentech	I	Solid tumors
PX-866	PI3K	ProIX	I	Solid tumors
SF1126	PI3K	Semafore	I	Solid tumors
Everolimus	mTOR	Novartis	II	Colon cancer (combination with cetuximab)

Citation: Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871
URL: https://www.wjgnet.com/1007-9327/full/v20/i29/9862.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i29.9862

Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871 [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.